AstraZeneca Discontinues Volrustomig Phase III eVOLVE-Lung02 study evaluating the bispecific antibody in combination with chemotherapy for patients with first-line metastatic non-small cell lung cancer (mNSCLC) whose tumors express PD-L1 levels under 50%. The global trial evaluated volrustomig plus chemotherapy against the standard-of-care regimen of pembrolizumab plus chemotherapy. Industry analysts and healthcare professionals are tracking therapeutic updates in AstraZeneca’s latest update.
The decision to stop the trial stems from a planned data review by the Independent Data Monitoring Committee (IDMC). According to the IDMC’s findings, the volrustomig combination was unlikely to demonstrate statistical significance in either of its dual primary endpoints, progression-free survival (PFS) or overall survival (OS), within the primary analysis cohort of patients with PD-L1 negative (<1%) tumors compared to pembrolizumab plus chemotherapy. Despite the efficacy shortfall, safety assessments confirmed that the combination displayed a profile consistent with the individual agent profiles, revealing no new safety signals. AstraZeneca has stated it will coordinate with trial investigators to manage patient continuity and appropriate follow-up care.
Susan Galbraith, Executive Vice President of Oncology Haematology R&D at AstraZeneca, noted that the eVOLVE-Lung02 study was intended to improve outcomes in patient populations with lower PD-L1 expression that often experience lower durability with standard regimens. While the results in mNSCLC were disappointing, AstraZeneca confirmed that learnings from this trial will inform ongoing oncology development. Other major trials in the AstraZeneca volrustomig Phase III trial pipeline remain active as planned across distinct indications, including cervical cancer, head and neck squamous cell carcinoma, and mesothelioma.
Key Parameters and Specifications of the Volrustomig Phase III Trial
The randomized, open-label, multi-center global eVOLVE-Lung02 study enrolled 895 patients across 25 countries to benchmark volrustomig against active controls. The table below presents the primary trial parameters and endpoint structures:
| Metric / Specification | Study Detail |
| Trial Name | eVOLVE-Lung02 |
| Study Phase | Phase III |
| Sponsor / Company | AstraZeneca |
| Investigational Agent | Volrustomig (Bispecific antibody targeting PD-1 and CTLA-4) |
| Comparator Agent | Pembrolizumab |
| Target Indication | 1st-line Metastatic Non-Small Cell Lung Cancer (mNSCLC) |
| Tumor Biomarker Selection | PD-L1 <50% (Primary Analysis Cohort: PD-L1 <1%) |
| Total Patient Enrollment | 895 patients across 25 countries |
| Dual Primary Endpoints | Progression-Free Survival (PFS) & Overall Survival (OS) in PD-L1 <1% population |
| Secondary Endpoints | PFS & OS in Intent-To-Treat (ITT) population (PD-L1 <50%) |
| Experimental Arm Dosing | Volrustomig 750mg IV + Chemotherapy Q3W (4 cycles) $\rightarrow$ Volrustomig Q3W |
| Control Arm Dosing | Pembrolizumab 200mg IV + Chemotherapy Q3W (4 cycles) $\rightarrow$ Pembrolizumab Q3W (up to 24 mos.) |
| Trial Outcome Status | Discontinued based on IDMC recommendation |
Patients in the active arm of this AstraZeneca volrustomig Phase III trial received 750mg intravenous volrustomig with chemotherapy every three weeks for four cycles, followed by volrustomig monotherapy every three weeks. In contrast, patients randomized 1:1 to the control arm received 200mg pembrolizumab combined with chemotherapy on a matching 3-week schedule for up to 24 months or until disease progression or discontinuation criteria were met.
Lung cancer remains the leading cause of cancer mortality worldwide, representing nearly 23% of total cancer deaths as documented in the WHO IARC Lung Cancer Fact Sheet. Non-small cell lung cancer accounts for 80% to 85% of all lung cancer diagnoses according to the American Cancer Society, with a 5-year survival rate of approximately 12% for patients diagnosed at the metastatic stage. Volrustomig was engineered as a bispecific antibody to deliver targeted, dual blockade of PD-1 and CTLA-4 on the same T cell to overcome immune evasion.
